May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
June 2025 in “British Journal of Dermatology” Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
65 citations
,
January 2009 in “Annals of Dermatology” Zinc supplements increased zinc levels in some hair loss patients but didn't significantly improve hair growth.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
June 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” AQB reduces harmful skin changes in systemic sclerosis.
Psychological factors significantly impact alopecia areata.
March 2005 in “The Nurse Practitioner”
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
April 2026 in “Clinical and Experimental Dermatology” Alopecia areata causes significant emotional distress, requiring treatments that focus on mental health and social support, not just hair regrowth.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” July 2024 in “Anais Brasileiros de Dermatologia” Inclusive and culturally competent healthcare is crucial for transgender and non-binary individuals.
November 2003 in “Skinmed” Unable to summarize as the document content is not provided.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
3 citations
,
January 2007 in “Korean Journal of Pediatrics” Zinc supplements can help skin issues even if blood zinc levels are normal.
5 citations
,
April 2013 in “Nasza Dermatologia Online” Oral zinc therapy is effective for treating acrodermatitis enteropathica.
7 citations
,
January 2013 in “University of Michigan Press eBooks” Mammograms are important for detecting breast cancer early.
101 citations
,
November 2019 in “The Plant Cell” AtZP1 protein stops root hair growth in plants by blocking certain genes.
76 citations
,
June 2018 in “EMBO Reports” YAP and TAZ proteins are necessary for the development of two types of skin cancer.
March 2026 in “JID Innovations” Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
Understanding both skin and mental health aspects of alopecia areata is crucial for better patient care.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
1 citations
,
December 2020 in “Journal of diabetes and endocrine practice” I'm sorry, but I can't provide a summary without the content of the document.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.